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Summary. Background: Excess fibrin in blood vessels is cleared by plasmin, the key proteolytic enzyme in fibrinolysis. Neurological disorders and head trauma can result in the disruption of the neurovasculature and the entry of fibrin and other blood components into the brain, which may contribute to further neurological dysfunction. Objectives: While chronic fibrin deposition is often implicated in neurological disorders, the pathological contributions attributable specifically to fibrin have been difficult to ascertain. An animal model that spontaneously acquires fibrin deposits could allow researchers to better understand the impact of fibrin in neurological disorders. Methods: Brains of plasminogen (plg)-and tissue plasminogen activator (tPA)-deficient mice were examined and characterized with regard to fibrin accumulation, vascular and neuronal health, and inflammation. Furthermore, the inflammatory response following intrahippocampal lipopolysaccharide (LPS) injection was compared between plg À/À and wild type (WT) mice. Results and
Introduction
Neurological disorders and head trauma can result in the disruption of the neurovasculature and the entry of blood proteins, such as fibrinogen, into the brain, which may promote deleterious effects when introduced into the brain parenchyma. Fibrinogen is a circulating protein that is required for normal hemostasis. In the event of injury, fibrinogen is cleaved by thrombin to form fibrin, the primary protein component of blood clots. Fibrin is normally excluded from the brain by the blood-brain barrier (BBB). However, following head trauma and chronic neurological disorders such as multiple sclerosis (MS) and Alzheimer's disease (AD), the persistence of fibrin in the brain can potentially worsen and accelerate disease pathology [1] . Both MS and AD patients exhibit increased BBB permeability and fibrin immunostaining in the brain parenchyma [2, 3] . In experiments with AD mouse models, fibrin levels correlate with neuroinflammation, BBB disruption, cerebral amyloid angiopathy, and cognitive dysfunction [4, 5] . Moreover, depletion of fibrin reduces pathological severity in murine models of MS [6, 7] and AD [5] . While chronic fibrin deposition is implicated in the progression of these diseases, the contributions attributable specifically to fibrin are difficult to ascertain. Characterization of its effects requires an animal model that spontaneously acquires brain fibrin deposits in the absence of additional autoimmune or neurodegenerative features. In the WT animal, levels of deposited fibrin are tightly regulated by fibrinolysis, which is driven by the enzyme plasmin. Plasminogen, the precursor of plasmin, binds fibrin and is converted to plasmin by plasminogen activators [8] . Plasmin then degrades fibrin through proteolytic cleavage at specific amino acid residues [8] . Mice deficient in plasminogen (plg develop spontaneous thrombotic lesions in visceral organs that are associated with fibrin deposition [9, 10] . Genetic depletion of fibrin in these animals corrects these phenotypes and restores their normal lifespan [11] , suggesting that the widespread deposition of fibrin is toxic. However, chronic fibrin deposition in the brain and its subsequent effects have yet to be investigated.
In the present study, we discovered naturally occurring fibrin deposits in the brains of plg À/À mice and investigated the effects of these deposits on vascular, neuronal, and inflammatory markers. Additionally, we compared the inflammatory response to lipopolysaccharide (LPS) in the brains of WT and plg À/À mice.
Material and methods

Animals
Plg À/À [9, 10] , tPA À/À [12] , and WT littermates or C57/BL6
(Jackson Laboratories, Bar Harbor, ME, USA) mice were used. Genotypes were determined by PCR analysis of tail tissue samples. Both genders of plg À/À mice were used in all experiments, and the proportion of females to males was consistent. Mice were maintained in The Rockefeller University's Comparative Biosciences Center and treated in accordance with IACUC-approved protocols.
Stereotactic intrahippocampal injection of LPS
The plg À/À and WT control mice (n = 6-8 animals per genotype and gender, 12-14 weeks of age) were anesthetized with an intraperitoneal injection of tribromoethanol (0.02 mL g body weight
À1
) and atropine (0.6 lg g body weight
) and immobilized in a stereotaxic apparatus. A unilateral intrahippocampal injection of 4 lg lL À1 LPS
(1 lL, Escherichia coli; Sigma Aldrich, St. Louis, MO, USA) was delivered over a 2-min period. Stereotaxic coordinates from bregma were 2.5 mm posterior, 1.7 mm lateral, and 1.8 mm ventral. Mice were anesthetized 24 h after intrahippocampal LPS injection with an intraperitoneal injection of tribromoethanol and perfused with a solution of 0.9% saline containing heparin. Left and right hippocampi were dissected and stored at À80°C before RNA or protein extraction, or the whole brain was frozen in Tissue-Tek optimal cutting temperature (OCT) compound (Sakura Finetek, Torrance, CA, USA) before immunohistochemical analysis.
RNA extraction and qPCR
Total RNA was extracted from mouse brain tissue using the Qiagen RNeasy procedure (Qiagen, Valencia, CA, USA), and recovered RNA concentrations were measured using a NanoDrop â ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). RNA was converted to cDNA with a GeneAmp RNA PCR kit (Applied Biosystems, Foster City, CA, USA). Target mRNA was quantified by quantitative-PCR (qPCR) and normalized relative to ribosomal 18S (r18S) mRNA. The qPCR analysis was performed in a 96-well format on an ABI Prism 7900HT Sequence Detection System (Applied Biosystems). For amplification of target genes, predesigned primers and probes from Applied Biosystems were used: interleukin-1b (IL-1b) (Mm00434228_m1), tumor necrosis factor-a (TNF-a) (Mm00443260_g1), interleukin-6 (IL-6) (Mm00446190_m1), and r18S (Mm02601777_g1).
Relative quantification of gene expression was analyzed as a treatment-to-control expression ratio using the comparative △△C t method. Each sample was analyzed in triplicate on two separate occasions.
Protein extraction and ELISA
Total protein was extracted from mouse brain tissue using a neuronal protein extraction reagent (Thermo Scientific, Waltham, MA, USA), according to the manufacturer's protocol. Antigen levels of TNF-a, IL-6, and IL-1b were determined by mouse ELISA kits (Abcam, Cambridge, MA, USA), according to the manufacturer's protocol. Each sample was tested in duplicate.
Immunohistochemistry
Plg À/À (n = 15 animals including nine females and six males, 2-14 weeks of age used for time course analysis of parenchymal fibrin deposition, and n = 12 animals including six females and six males, 12-14 weeks-of age used for all other immunohistological analyses), tPA À/À (n = 4 animals including three females and one male, 14-16 weeks of age), and WT (n = 7 animals including four females and three males, 12-13 weeks of age) mice were perfused with a solution of 0.9% saline containing heparin and their brains were extracted, frozen in OCT compound, and sliced coronally with a cryostat to produce 20 lm-thick sections. Sections were mounted on slides, air dried for 30 min, and fixed in ethanol at À20°C. For fibrin and a-smooth muscle actin (a-SMA), glial fibrillary acid protein (GFAP), neutrophils (NIMP-R14), albumin, microtubule-associated protein-2 (MAP-2), CD45, or CD31 co-immunostaining, slides were blocked in 3% goat serum/0.25% Triton X-100 in PBS. For fibrin co-staining with CD11b or ionized calcium binding adaptor molecule-1 (Iba-1), slides were blocked in 3% goat serum in PBS. Primary antibodies were incubated overnight at 4°C, and secondary fluorescence antibodies were incubated for 1 h at room temperature in the same blocking solution. Also, 4 0 ,6-diaminidine-2-phenylindole (DAPI) was included in the secondary solution to visualize nuclei. For fibrin co-staining with NeuN, the M.O.M. Kit (Vector Laboratories, Burlingame, CA, USA) was used according to the manufacturer's instructions. All slides were then incubated with anti-fibrin(ogen)-FITC antibody for 2 h at room temperature and subsequently with Sudan Black B solution (Sigma-Aldrich, St. Louis, MO, USA) for 1 min. Vectashield mounting medium (Vector) was used to affix coverslips.
For fibrin and Fluoro-Jade C (FJC; Histo-Chem, Inc., Jefferson, AR, USA) co-staining, slides were blocked in 3% goat serum/0.25% Triton X-100 in PBS and incubated with anti-fibrin(ogen) antibody overnight in the same blocking solution. Subsequently, the sections were incubated for 1 h with Alexa Fluor 555 and DAPI and counterstained for FJC following the manufacturer's instructions. Briefly, sections were immersed in 0.06% KMnO 4 and subsequently in FJC solution (0.00025% FJC in 0.1% acetic acid) for 15 min at room temperature. FJC-stained slides were dried at 50°C and immersed in clearing agent (CitriSolv TM ; Fisher Scientific, Pittsburgh, PA, USA), and coverslips were affixed with Vectamount (Vector).
Collagenase-induced intracerebral hemorraghic mouse brain tissue sections [13] were used as positive controls for albumin, CD45, and neutrophil immunostainings, whereas brain tissue sections from AD mice [14] were used as positive controls for Iba-1, CD11b, and GFAP immunostaining. Brain sections from mice exposed to an intrahippocampal kainate injection [15] were used as positive control for FJC immunostaining. Replacement of the primary antibodies by PBS served as negative controls for all stainings.
Primary antibodies used in the study are provided in Table 1 . The secondary antibodies used: Alexa Fluor 568 goat anti-rat, Alexa Fluor 568 goat anti-chicken, and Alexa Fluor 555 goat anti-rabbit were all purchased from Invitrogen (Grand Island, NY, USA). Streptavidin Texas Red (Vector) was used with the M.O.M. kit.
Microscopy and immunohistological quantification
For all immunohistochemical analyses, coronal whole brain tissue sections (n = 3-7 sections per mouse) were examined using a Zeiss Axiovert 200 microscope (Zeiss, Thornwood, NY, USA) with AxioVision v4.8.1.0 software. Quantifications were performed using ImageJ software (NIH, Bethesda, MD, USA). Quantitative image analysis for the LPS-injected mouse sections was performed on three equally spaced sections through the level of the injection site (AP AE 1.0 mm). Identical intensity thresholds were applied to each image set. To determine the degree of fibrin deposition, whole tissue sections that included the cortex, hippocampus, and thalamus were examined, and the total number of fibrin deposits per mouse brain section was determined. Quantification of neuronal and dendritic density was performed on images acquired from non-overlapping cortical areas (that were at least 100 lm apart) containing or lacking fibrin deposits. Fibrin deposits overlapping with intense CD11b/Iba-1 or GFAP immunostaining were considered positive for reactive microglia and astrocytes, respectively. Micrographs for all figures were taken using a TCS SP8 laser scanning confocal microscope (Leica Microsystems, Wetzlar, Germany). 
Statistical analysis
Values are presented as mean AE SEM, and P < 0.05 was considered statistically significant. Linear regression was used to analyze the time course of fibrin deposition ( 
Results
Fibrin accumulates in the brains of plg À/À and tPA À/À mice Plg À/À mice accumulate fibrin in visceral organs including the lung, liver, stomach, gastrointestinal tract, rectum, thymus, and adrenal tissue [9, 10] . To determine whether fibrin may also be deposited in the CNS of these mice, brain sections from plg À/À and WT animals were immunostained for fibrin. The plg À/À brains exhibited widespread parenchymal fibrin deposits, which were fibrillar in appearance and ranged from 5 lm to several hundred microns in diameter (Fig. 1A,B ). These deposits did not appear to be region-specific and were found throughout the brain parenchyma (e.g. cortex, hippocampus, and thalamus; olfactory bulbs were not examined). Fibrin deposition was observed in plg À/À animals as young as 2 weeks of age and increased significantly in number ( Fig. 1C ) and size (data not shown) as the animals matured. Despite evident gender differences observed in Chicken Albumin Abcam molecular pathways associated with tumor growth in plg À/À mice [16] , there was no significant difference in the total number of fibrin deposits between female and male plg À/À mouse brains. Parenchymal fibrin deposits were also found throughout the brains of tPA À/À mice, and there was no significant difference in the number of fibrin deposits between tPA À/À and plg À/À mice at~14 weeks of age (Fig. 1C) . In contrast, brain parenchymal fibrin deposits were not observed in WT controls.
To identify the source of the fibrin deposits, brain sections from plg
, and WT mice were co-immunostained for fibrin and CD31/PECAM-1, a marker for vascular endothelial cells [17] . While there was no evidence of extravascular fibrin deposition in WT mice ( Fig. 2A) , parenchymal fibrin deposits were often observed in direct or close proximity to blood vessels in plg À/À (Fig. 2B ) and tPA À/À (data not shown) mice. Costaining for a-SMA, a protein present in contractile vessels [18] , demonstrated that some fibrin deposits may arise from brain arterioles (Fig. 2C) . To further investigate the source of parenchymal fibrin deposits, brain tissue sections were stained for albumin. In both plg À/À and tPA À/À mice, albumin-positive immunoreactive areas were occasionally observed in the brain parenchyma (data not shown), thus indicating impairment of neurovascular integrity in these mice.
Neuronal health in plg À/À and tPA À/À mouse brains is not affected by fibrin deposits
In plg À/À mice, necrosis is often observed adjacent to thrombotic lesions in the liver and gastrointestinal tract [9] . To determine if brain parenchymal fibrin deposits produce widespread neuronal death, brain sections from
, and WT mice were co-immunostained for fibrin and NeuN, a neuronal nuclei marker [19] . Parenchymal fibrin deposits did not appear to influence neuronal density in plg À/À (Fig. 3A,B) or tPA À/À mice (data not shown; mean and SEM, 3.27 AE 0.65 in fibrin and 2.9 AE 0.31 in non-fibrin areas, n = 4 animals). Moreover, staining of brain sections with FJC, a marker of neuronal degeneration [20] , failed to show degenerating neurons around fibrin deposits in plg À/À (Fig. 3C ) and tPA
(data not shown) mice. Tissue sections from brains of mice injected intrahippocampally with kainate were used as positive controls for FJC staining (Fig. S1A) . The effects of fibrin deposits on dendritic density were also investigated. Co-staining with antibodies against fibrin and MAP-2, a marker of dendritic density [21] , demonstrated co-localization at sites of fibrin deposits without any significant reduction in dendritic marker intensity in plg À/À (Fig. 3D,E) and tPA À/À mice (data not shown; mean and SEM, 9.89 AE 0.84 in fibrin and 11.36 AE 0.90 in non-fibrin areas, n = 4 animals). Furthermore, there was no significant difference in neuronal or dendritic density between female and male plg À/À mouse brains (data not shown). Together, these results suggest that gross neuronal and dendritic densities are not affected by the close proximity to fibrin deposits.
Fibrin deposits in plg À/À and tPA À/À mouse brains colocalize with active astrocytes but not microglia
The primary mediators of inflammation in the CNS are microglia and astrocytes, and fibrin can activate both of these cell types [4, 22, 23] . Fibrin can also bind the integrin a M b 2 receptor CD11b found on monocytes, macrophages, and microglia [22, 24] , which can result in increased expression of proinflammatory cytokines [25, 26] . The inflammatory properties of fibrin deposits in plg À/À and tPA À/À mouse brains were examined by looking for colocalization between deposits and activated microglia or astrocytes. Activated microglia were identified by staining for CD11b [27] and Iba-1 [28] . The vast majority of fibrin deposits in plg À/À mice failed to co-localize with CD11b
or Iba-1 immunopositive cells (98.9%, n = 204 deposits, and 95.7%, n = 192 deposits, respectively) (Fig. 4A,B,E) . This observation was also true for large fibrin deposits (≥ 100 lm), suggesting that the lack of microglial response to the deposits was not a matter of scale. Immunostaining for GFAP, a cytoskeletal marker for active astrocytes [29] , demonstrated that more than half of the fibrin deposits (59.5%, n = 177 deposits) associated with GFAP-positive cells in plg À/À mouse brains (Fig. 4C,E ).
No significant difference was observed in degree of co-localization of fibrin with activated microglia or astrocytes between female and male plg À/À mice (data not shown). Immunostaining of tPA À/À mouse brain tissue demonstrated a similar inflammatory response to fibrin deposits in that the vast majority of fibrin deposits failed to co-localize with CD11b (98.3%, n = 44 deposits) and Iba-1 (97.3%, n = 56 deposits), whereas approximately half of the deposits co-localized with GFAP (52.5%, n = 32 deposits). There were no significant differences in microglial or astrocyte activation in areas lacking fibrin deposits among plg À/À , tPA À/À , and WT mice (data not shown). AD mouse brains were used as positive control tissue for CD11b, Iba-1, and GFAP immunostaining ( Fig. S1B-D) .
Fibrin deposits are not associated with neutrophil or macrophage infiltration in plg À/À or tPA À/À mouse brains
Plasmin and plasmin-derived fibrin(ogen) degradation products are potent chemotactic proteins for inflammatory cells, including macrophages and neutrophils [30] . To investigate if fibrin deposition results in recruitment of inflammatory cells, brains sections from plg À/À and tPA À/À mice were co-immunostained for fibrin and CD45, a marker for macrophages/leukocytes [31] , and for fibrin and neutrophils. The majority of fibrin deposits failed to co-localize with CD45 ( Fig. 4D,E (n = 24-29 deposits) failed to co-localize with CD45 and neutrophils, respectively (data not shown). Brain tissue sections from mice with intracerebral hemorrhage were used as positive controls for CD45 staining (Fig. S1E) .
Reduced neuroinflammatory response to LPS in plg À/À mice Because fibrin deposits in plg À/À mouse brains did not provoke a significant activation of microglia, we hypothesized that these animals may have a compromised inflammatory response in the CNS. To test this idea, the response to LPS, a common inflammagen used to activate microglia and provoke induction of proinflammatory cytokine expression in vivo [32] , was compared between plg À/À and WT mouse brains. Animals received a unilateral intrahippocampal injection of LPS, and the activation of microglia and astrocytes as well as the expression of proinflammatory cytokines were analyzed 24 h later. Immuno- (E) Pie graphs show the percentage of fibrin deposits that co-localize with CD11b, Iba-1, GFAP, and CD45 staining (n = 204 deposits for FBCD11b co-localization; n = 192 deposits for FB-Iba-1 co-localization; n = 177 deposits for FB-GFAP co-localization, and n = 71 for FB-CD45 co-localization).
histochemical analysis using anti-CD11b antibody revealed that activation of microglia was markedly reduced in the LPS-injected hemispheres of plg À/À compared to WT mice (Fig. 5A vs. B) as both CD11b fluorescence intensity (Fig. 5C ) and CD11b immunoreactive area (Fig. 5D ) were significantly lower in plg À/À compared to controls. In contrast, there was no significant difference in astrocyte activation, measured by fluorescence intensity and immunoreactive area of GFAP, between LPS-injected hemispheres of plg À/À and WT mice (data not shown). Furthermore, a pronounced difference in the induction of proinflammatory cytokine expression was observed between the two genotypes. As expected [32] , intrahippocampal LPS injection resulted in a marked up-regulation of TNFa, IL-1b, and IL-6 mRNA (Fig. 6A ,C,E) and protein expression (Fig. 6B,D,F ) levels compared to the contralateral non-injected hippocampus. On the contrary, up-regulation of these proinflammatory cytokines was significantly reduced in the LPS-injected plg À/À mouse hippocampus compared to the LPS-injected WT mouse hippocampus (Fig. 6) . Moreover, there was no significant up-regulation of proinflammatory cytokine protein levels after LPS injection in the plg À/À mouse hippocampus compared to the contralateral non-injected hippocampus (Fig. 6B,D,F) . No significant differences in expression levels of these cytokines were observed between non-injected WT and plg À/À mouse brains. Together, these results suggest that plasmin is required for a complete inflammatory response in the mouse brain.
Discussion
Mice deficient in plasminogen have been extensively used for unraveling the role of plasmin(ogen) and its substrate fibrin in physiological and pathophysiological processes. However, the endogenous accumulation of fibrin and its biological effects in the brains of these mice have not been previously investigated. The studies discussed here show that plg À/À mice accumulate brain parenchymal fibrin deposits early in life (Fig. 1 ) that appear to result from reduced neurovascular integrity (Fig. 2 ), yet these deposits do not impact neuronal health (Fig. 3) or induce local inflammation (Fig. 4) . Furthermore, these studies also show that the neuroinflammatory response is impaired in plg À/À mice when challenged with a more general inflammatory mediator (Figs 5 and 6 ). Mice deficient in tPA also exhibit accumulation of fibrin in their brain parenchyma (Fig. 1) without showing any significant inflammatory response to these deposits, thus implying that plasmin, rather than plasminogen, is ultimately required for a complete inflammatory response to fibrin in the CNS. Fibrin deposits in close proximity to blood vessels and the abundant albumin immunoreactivity in the plg mouse brain parenchyma ( Fig. 2 and data not shown, respectively) are supported by a previous study showing impairments of neurovascular integrity in plg À/À mice at 3 months of age [4] . Similarly, we identified fibrin deposits and altered BBB properties in tPA À/À mice (data not shown). Although it is unclear as to how plasmin(ogen) and tPA impact neurovascular integrity, studies indicate that changes in BBB permeability during pathophysiological conditions may occur via tPA's interaction with lipoprotein receptor-related protein and subsequent activation of matrix metalloproteinases and/or platelet-derived growth factor-CC, which can be associated with detachment of astrocytic endfeet from the basal lamina (reviewed in Ref. [33] ). Others have reported studies showing that fibrin(ogen) decreases expression levels of tight junction proteins in vitro [34, 35] . Thus, it is possible that our observations in the plg À/À and tPA À/À mice result from a direct effect of fibrin on cerebrovascular endothelial cells rather than an effect of tPA activity on BBB permeability. We hypothesize that this compromised neurovasculature, together with widespread fibrin deposition, might lead to deficits in cerebral blood flow in these mice. Since hypoperfusion can lead to cognitive decline [36, 37] , our current findings support our previous report that plg À/À mice exhibit memory deficits [5] . Our results also correlate well with what is observed in chronic neurodegenerative diseases in humans, such as MS and AD. Studies on postmortem tissue from these patients often show reduced neurovascular integrity and leakage of fibrin into the brain parenchyma [1] [2] [3] . AD and MS patients also present with hypoperfusion [37, 38] , which could ultimately lead to their cognitive deficits. Future studies that examine the role of plasmin in neurodegenerative disease pathophysiology may be warranted as plasmin may have a significant impact on neurovascular integrity.
Since the extravasation of fibrin into the nervous system can induce local inflammation and may contribute to neurological dysfunction [3] [4] [5] [6] , we anticipated that these chronic fibrin deposits in plg À/À mouse brains would trigger the inflammatory response and subsequently impact neuronal health. Intriguingly, our investigation did not reveal any substantial effect of fibrin deposits on inflammatory/ neuronal markers or vascular recruitment of inflammatory cells. This lack of neuroinflammatory response to fibrin prompted us to perform additional in vivo experiments to determine whether this response was fibrin specific or more general. The plg À/À and WT mice were exposed to the endotoxin LPS via an intrahippocampal injection, and the local inflammatory response was analyzed. These experiments showed that activation of microglial cells and induction of proinflammatory cytokines were significantly reduced in plg À/À animals following LPS challenge compared to WT mice. Our findings agree with reports showing significantly reduced activation of immune cells and reduced induction of proinflammatory cytokine expression in response to inflammatory stimuli in peripheral tissues of plg À/À mice [39] [40] [41] . Supporting our result that fibrin deposition does not induce neuronal death in the absence of neuroinflammation is the report by Davalos et al. [42] , which showed that mutant mice expressing fibrinogen c390-396, which is unable to interact with microglial receptors and induce an inflammatory response, are protected from neuronal damage. Also in line with our results is the study by Schachtrup et al. [43] , which showed that fibrinogen can affect astrocytes independently of microglial activation. Thus, our combined data suggest that plasmin (ogen) is necessary for a complete inflammatory response peripherally as well as centrally. Various mechanisms may explain the impaired neuroinflammatory response in plg À/À mice. It has been well established that plasmin and its degradation products are potent activators of inflammatory cells [44] [45] [46] . Plasmin also plays an important role in cell migration by facilitating degradation of matrix proteins and activating matrix metalloproteases [47] , which is supported by the present finding that fibrin deposits in plg À/À mice are not associated with the recruitment of macrophages and neutrophils. Therefore, the impaired inflammatory response in the brains of plg À/À mice may result from a lack of plasmindependent recruitment and activation of inflammatory cells at sites of fibrin deposition or inflammation. This notion is supported by previous studies in plg À/À mice, demonstrating that cell migration associated with the inflammatory response is compromised in peripheral organs of these mice. For example, plg À/À mice show diminished migration of smooth muscle cells during wound healing [48] , as well as reduced recruitment of macrophages and neutrophils in response to inflammatory mediators [49] and biomaterials [50] . Detailed studies to elucidate the specific roles of plasmin in the neuroinflammatory response are warranted. However, given the blunted inflammatory process in plg À/À mice, caution should be taken when utilizing this animal model in studies involving neurological disorders and neuroinflammation.
Based on the results presented in this study, we show that fibrin does not affect neuronal health in the absence of inflammation and that plasmin plays an essential role in maintaining a normal proinflammatory capability in the CNS.
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